The evolution of therapeutic modalities drives the adoption of single-use technologies.
Despite its understandable hesitancy, the pharma industry is facing a need for more widespread adoption of cloud-based solutions.
Given the criticality of fill/finish processes, it is clear that automation is the next technological step.
Two popular methods for detecting protein aggregates are analytical ultracentrifugation (AUC) and size-exclusion chromatography?multiangle light scattering (SEC?MALS). These techniques? results correlate relatively well, but each one has its own strengths.
AstraZeneca agreed to settle a sex-discrimination lawsuit by paying $250,000 to 124 women who worked at the company's Philadelphia Business Center.
Can microdosing make medicines safer and more effective for children?
More sophisticated biological expression systems expand the functionality of the traditional systems for protein synthesis.
The authors compare three systems of single-screw extrusion using binary formulations for their suitability for producing pellets of various formulations and under various spheronization conditions.
Academic–industry partnerships are increasingly important in biopharmaceutical innovation.
Editor's picks of new manufacturing products for June 2011.
A recent industry survey shows keen interest in improving bioreactors and cell-culture media.
The study results suggested that Pluronic F127 might be a potent inhibitor of drug precipitation for Labrasol formulations.
Lessons from the earthquake in Japan show the vulnerability of the bio/pharma supply chain.
Industry struggles to curb drug abuse, diversion, and disruptions in supply.
Sometimes, there are just too many cooks in the kitchen.
A holistic approach to establishing robust control measures.
FDA added a searchable database of inspection data to its website. The database lists the names and addresses of facilities that the agency inspected during fiscal years 2009 and 2010.
FDA weighs multiple views regarding the Biologics Price Competition and Innovation Act.
Industry associations will soon provide new recommendations about extractables and leachables.
This month's BIO Convention will encourage needed conversations.
During an eight-day series of meetings that concluded on May 24, 2011, the World Health Assembly passed 28 resolutions and adopted three decisions to guide the organization?s work and address global health issues.
India's drug pricing authority increased the retail costs of certain domestically manufactured drugs, but not those of imported drug products. Pharma is asking why.
Effective containment in API and drug-product manufacturing encompasses a variety of process, equipment, and operational issues.
Regions around the world are starting to follow the US trend in disposables and are working to solve common challenges.
Takeda Pharmaceutical has agreed to acquire Nycomed, a Swiss pharmaceutical company for $13.5 billion, excluding Nycomed's US dermatology business. The deal is intended to increase Takeda's presence in European and emerging markets.
Global spending on medicines will total almost $1.1 trillion by 2015, according to an IMS Institute for Healthcare Informatics study.
Teva Pharmaceutical Industries agreed to pay shareholders $460 million in cash to acquire a 57% stake in Taiyo Pharmaceutical Industry. Teva also will offer to buy all outstanding shares of Taiyo.
Johnson & Johnson subsidiary Janssen-Cilag International reported that the company is working with regulatory authorities in five countries to address trace amounts of 2,4,6- tribromoanisole identified in five batches of the HIV/AIDS medicine Prezista.
